Crystalline Solid Dispersion for Poorly Water-Soluble Drugs
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Poorly water-soluble drugs exhibit low bioavailability and efficacy due to their crystalline structure, leading to limited absorption and dissolution, and are not suitable for intravenous administration as they can cause thrombosis or stroke.
Innovation Solution
A crystalline solid dispersion (CSD) process is developed, where a compound with low water solubility is dispersed in a sodium acetate crystal matrix using glacial acetic acid, followed by freeze-drying to enhance aqueous solubility and bioavailability, using a method that prevents thermal degradation and recrystallization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If the compound is dispersed in a crystalline carrier using the melting method, then the aqueous solubility is improved, but the compound undergoes thermal degradation and physical degradation during melting and crushing
Solution Approach 1:
The patent changes the processing parameters from high-temperature melting to low-temperature freeze-drying. The compound is dispersed in the crystalline carrier at low temperatures and then freeze-dried to remove the solvent, achieving solubility improvement without thermal degradation.
Solution Approach 2:
The patent replaces the mechanical melting and crushing process with a freeze-drying process. Instead of using heat and mechanical force to achieve dispersion, the invention uses phase change (freezing and sublimation) to achieve the same result with minimal mechanical stress on the compound.
2Productivity
If the compound is dispersed in a crystalline carrier, then the dissolution rate is enhanced, but the compound may rapidly crystallize when the carrier-drug mixture is not at the exact eutectic molar composition
Solution Approach 1:
The patent uses an intermediary solvent system (aqueous buffer solution) to facilitate the dispersion of the compound in the crystalline carrier. This intermediary medium allows for controlled incorporation of the compound into the carrier structure, preventing rapid crystallization while maintaining dissolution enhancement.
Solution Approach 2:
The patent performs preliminary dispersion of the compound in the crystalline carrier before final formulation. By pre-dispersing the compound in the carrier matrix under controlled conditions, the invention prevents subsequent rapid crystallization during storage or administration.
3Device complexity
If the compound is administered as poorly water-soluble solid aggregates, then the formulation is simple, but it can potentially lead to thrombosis or stroke and is not suitable for intravenous administration
Solution Approach 1:
The patent segments the compound into fine particles dispersed within a crystalline carrier matrix. This segmentation reduces particle size from large aggregates to microscopic dispersed particles, eliminating thrombosis risk while maintaining formulation simplicity through the use of a single carrier system.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The CSD process significantly improves the aqueous solubility and bioavailability of poorly water-soluble drugs, such as docetaxel, by reducing particle size and enhancing dissolution rates, while maintaining chemical stability and safety for intravenous administration.
Implementation Method 1
followed by freeze-drying to enhance aqueous solubility and bioavailability
Implementation Method 2
dispersed in a sodium acetate crystal matrix using glacial acetic acid
Data Source
AI summary
A method for forming crystalline solid dispersions (CSDs) of a pharmaceutical agent with low water solubility is described. The properties of the CSDs are described. Also described is the enhancement of bioavailability of the pharmaceutical agent resulting from formation of the CSD.